About AZRX

AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819-SD recombinant lipase for EPI is the Company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The Company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

AZRX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VTI Vanguard Total Stock Market ETF 108.6 B 1.086E+11 3,570 3570 0.0% 0 29 K 29016
VXF Vanguard Extended Market ETF 6.5 B 6.5E+09 3,237 3237 0.0% 0 24 K 24296
IWC iShares Microcap ETF 852.8 M 8.52758E+08 1,426 1426 0.0% 0 42 K 41558